Payment overview · 2025
General Payments
$487.79
22 reported records · 12 companies
Healthcare provider profile · identity verified
Joe Hebert, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · DARDANELLE, AR · NPI 1184161895
Verified facts
What the public records show
CMS Open Payments records show Joe Hebert, APRN received $487.79 in general payments during 2025 across 22 reported records.
Novartis Pharmaceuticals Corporation accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $107.31 | 22.0% | 6 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $72.50 | 14.9% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$63.52 | 13.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $53.53 | 11.0% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $32.27 | 6.6% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $31.90 | 6.5% | 2 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$27.28 | 5.6% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.20 | 5.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.98 | 4.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.73 | 4.0% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $17.26 | 3.5% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $15.31 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $415.29 | 21 |
| Education | $72.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $107.31 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $53.53 | 3 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $39.75 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $32.27 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $31.90 | 2 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $27.28 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $25.20 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $21.98 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 266 | 45 |
| Omeprazole | Omeprazole | 266 | 50 |
| Atorvastatin Calcium | Atorvastatin Calcium | 260 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 247 | 44 |
| Lisinopril | Lisinopril | 194 | 48 |
| Prednisone | Prednisone | 173 | 105 |
| Losartan Potassium | Losartan Potassium | 168 | 28 |
| Meloxicam | Meloxicam | 165 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 152 | 37 |
| Ozempic | Semaglutide | 150 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 141 | 26 |
| Amlodipine Besylate | Amlodipine Besylate | 132 | 25 |
| Clonazepam | Clonazepam | 123 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 32 |
| Alprazolam | Alprazolam | 119 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 110 | 27 |
| Atenolol | Atenolol | 109 | 21 |
| Metformin Hcl | Metformin Hcl | 103 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 15 |
| Allopurinol | Allopurinol | 97 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 19 |
| Fenofibrate | Fenofibrate | 96 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 12 |
| Metformin Hcl Er | Metformin Hcl | 86 | 19 |
| Celecoxib | Celecoxib | 81 | 15 |
| Ezetimibe | Ezetimibe | 81 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 80 | 11 |
| Sertraline Hcl | Sertraline Hcl | 80 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 77 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 75 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 65 | 52 |
| Farxiga | Dapagliflozin Propanediol | 64 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 61 | 15 |
| Pregabalin | Pregabalin | 60 | suppressed |
| Simvastatin | Simvastatin | 57 | 11 |
| Sucralfate | Sucralfate | 55 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 54 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 14 |
| Ondansetron Odt | Ondansetron | 53 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | suppressed |
| Carvedilol | Carvedilol | 52 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 41 |
| Furosemide | Furosemide | 47 | 13 |
| Buspirone Hcl | Buspirone Hcl | 46 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 46 | suppressed |
| Eszopiclone | Eszopiclone | 45 | suppressed |
| Mirtazapine | Mirtazapine | 45 | suppressed |
| Glipizide | Glipizide | 43 | suppressed |
| Azithromycin | Azithromycin | 42 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 11 |
| Montelukast Sodium | Montelukast Sodium | 42 | suppressed |
| Potassium Chloride | Potassium Chloride | 41 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Eliquis | Apixaban | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Mupirocin | Mupirocin | 31 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 30 | suppressed |
| Bumetanide | Bumetanide | 29 | suppressed |
| Fluconazole | Fluconazole | 28 | 25 |
| Naproxen | Naproxen | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 27 | 20 |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 22 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | 16 |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 14 |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Armodafinil | Armodafinil | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Easy Touch | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Paliperidone Er | Paliperidone | 11 | suppressed |
| Thioridazine Hcl | Thioridazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $487.79 · 22 records | Novartis Pharmaceuticals Corporation | BOTOX, CAPLYTA, INGREZZA, KESIMPTA, Leqembi, Ocrevus Zunovo, QULIPTA, UBRELVY, ULTOMIRIS, VALTOCO, VYEPTI, VYVGART HYTRULO | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error